...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
【24h】

Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.

机译:设计和合成褪黑激素结合位点MT3上作为新配体的萘衍生物。

获取原文
获取原文并翻译 | 示例
           

摘要

Naphthalenic analogs of MCA-NAT (5-methoxycarbonylamino-N-acetyltryptamine) have been synthesized and evaluated as melatonin receptor ligands. Introduction of a methoxycarbonylamino substituent at the C-7 position of the naphthalenic nucleus yields MT3 selective ligands. This selectivity can be modulated with suitable variations of the C-7 position and the acyl group on the C-1 side chain. We identified new series of compounds with affinity for the MT3 binding site in the nanomolar range, and singled out a selective ligand, (N-[2-(7-methylsulfamoyl-naphth-1-yl)ethyl]acetamide (17), with a Ki of 4.9 nM and selectivity of 1024 and 2040 versus MT1 and MT2 receptors respectively.
机译:已经合成了MCA-NAT的萘类似物(5-甲氧基羰基氨基-N-乙酰基色胺),并作为褪黑激素受体配体进行了评估。在萘核的C-7位置引入甲氧羰基氨基取代基产生MT3选择性配体。可以通过C-7位置和C-1侧链上酰基的适当变化来调节这种选择性。我们确定了对MT3结合位点具有亲和力的新系列化合物,并选择了一个选择性配体(N- [2-(7-甲基氨磺酰基-萘-1-基)乙基]乙酰胺(17)相对于MT1和MT2受体,Ki为4.9 nM,选择性为1024和2040。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号